Outcomes of an International Workshop on Preconception Expanded Carrier Screening: Some Considerations for Governments by Caron M. Molster et al.
February 2017 | Volume 5 | Article 251
hypothesis and theory
published: 24 February 2017
doi: 10.3389/fpubh.2017.00025
Frontiers in Public Health | www.frontiersin.org
Edited by: 
Rumen Stefanov, 
Institute for Rare Diseases, Bulgaria
Reviewed by: 
Arnold Bosman, 
Transmissible, Netherlands  
M. Rashad Massoud, 
University Research Co., USA
*Correspondence:
Caron M. Molster 
caron.molster@health.wa.gov.au
†These authors have contributed 
equally to this work.
Specialty section: 
This article was submitted to 
Public Health Policy, 
a section of the journal 
Frontiers in Public Health
Received: 29 September 2016
Accepted: 09 February 2017
Published: 24 February 2017
Citation: 
Molster CM, Lister K, Metternick-
Jones S, Baynam G, Clarke AJ, 
Straub V, Dawkins HJS and Laing N 
(2017) Outcomes of an International 
Workshop on Preconception 
Expanded Carrier Screening: Some 
Considerations for Governments. 
Front. Public Health 5:25. 
doi: 10.3389/fpubh.2017.00025
outcomes of an international 
Workshop on preconception 
expanded Carrier screening: some 
Considerations for Governments
Caron M. Molster1*†, Karla Lister1†, Selina Metternick-Jones2, Gareth Baynam1,3,4,5,6,7,8, 
Angus John Clarke9, Volker Straub10, Hugh J. S. Dawkins1,11,12,13 and Nigel Laing14,15
1 Office of Population Health Genomics, Public Health Division, Department of Health Western Australia, Perth, WA, Australia, 
2 Sir Charles Gairdner Hospital, Perth, WA, Australia, 3 Genetic Services WA, Perth, WA, Australia, 4 School of Paediatrics and 
Child Health, University of Western Australia, Perth, WA, Australia, 5 Institute for Immunology and Infectious Diseases, 
Murdoch University, Perth, WA, Australia, 6 Telethon Kids Institute, University of Western Australia, Perth, WA, Australia, 
7 Western Australian Register of Developmental Anomalies, Perth, WA, Australia, 8 Spatial Sciences, Department of Science 
and Engineering, Curtin University, Perth, WA, Australia, 9 Division of Cancer and Genetics, School of Medicine, Cardiff 
University, Cardiff, UK, 10 Institute of Human Genetics, University of Newcastle upon Tyne, Newcastle upon Tyne, UK, 
11 Centre for Comparative Genomics, Murdoch University, Perth, WA, Australia, 12 Centre for Population Health Research, 
Curtin University, Perth, WA, Australia, 13 School of Pathology and Laboratory Medicine, University of Western Australia, 
Perth, WA, Australia, 14 Centre for Medical Research, Harry Perkins Institute of Medical Research, University of Western 
Australia, Perth, WA, Australia, 15 Neurogenetics Unit, Department of Diagnostic Genomics, PathWest Laboratory Medicine, 
Department of Health Western Australia, Perth, WA, Australia
Background: Consideration of expanded carrier screening has become an emerging 
issue for governments. However, traditional criteria for decision-making regarding 
screening programs do not incorporate all the issues relevant to expanded carrier 
screening. Further, there is a lack of consistent guidance in the literature regarding the 
development of appropriate criteria for government assessment of expanded carrier 
screening. Given this, a workshop was held to identify key public policy issues related to 
preconception expanded carrier screening, which governments should consider when 
deciding whether to publicly fund such programs.
Methods: In June 2015, a satellite workshop was held at the European Society of Human 
Genetics Conference. It was structured around two design features: (1) the provision of 
information from a range of perspectives and (2) small group deliberations on the key 
issues that governments need to consider and the benefits, risks, and challenges of 
implementing publicly funded whole-population preconception carrier screening.
results: Forty-one international experts attended the workshop. The deliberations 
centered primarily on the conditions to be tested and the elements of the screening 
program itself. Participants expected only severe conditions to be screened but were 
concerned about the lack of a consensus definition of “severe.” Issues raised regarding 
the screening program included the purpose, benefits, harms, target population, pro-
gram acceptability, components of a program, and economic evaluation. Participants 
also made arguments for consideration of the accuracy of screening tests.
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introdUCtion
Population-based screening programs are a public health 
approach implemented by many governments, which usu-
ally focus on a specific subpopulation defined by age, sex, and 
sometimes by ethnicity. Examples include newborn screening, 
prenatal screening, and screening for breast, bowel, and cervical 
cancer. In most countries, programs for screening the population 
to identify carriers of genetic diseases have not yet been adopted 
by governments. However, the possibility of offering such pro-
grams has become more salient in recent years in the wake of 
technology drivers such as the availability of relatively low cost 
massively parallel sequencing. Given this, a workshop was held 
with experts from a number of countries to identify key public 
policy issues related to preconception expanded carrier screen-
ing, which governments should consider before deciding whether 
to publicly fund such programs.
Carrier screening is a form of genetic testing that is used to 
determine a couple’s risk of having a child with a recessive genetic 
disorder, when there is no a priori risk based on personal or fam-
ily history (1). The process involves analyzing a sample of blood, 
or other biological material, for evidence of genetic mutations 
associated with autosomal-recessive and X-linked conditions. 
Carriers of autosomal-recessive conditions are people who have 
one copy of a gene mutation that can cause a condition in their 
offspring. If two carriers of a mutation in the same gene have 
children, their offspring have a one in four chance of having the 
condition. For women who carry a gene mutation associated 
with an X-linked condition, their children have a 50% chance of 
inheriting that gene mutation. Male children of these women are 
usually affected by the condition since they inherit their only copy 
of the X chromosome from their mother, while female children 
are usually protected from the condition by the inheritance of a 
second X chromosome from the father.
The members of a couple may undertake carrier screening 
simultaneously or sequentially, and screening can be performed 
in the preconception period or during pregnancy. If offered in the 
preconception period, carrier screening provides an opportunity 
to identify individuals who are at risk of having a child affected 
with a condition, before they become pregnant. Partners can 
then make informed reproductive choices including: not having 
a child at all; adoption; preimplantation genetic diagnosis (PGD) 
or in vitro fertilization (IVF) to avoid having an affected child; 
or to have a child naturally, with prior knowledge of their risk 
of having a child with a specific condition. Screening during the 
preconception period can be considered more favorable than 
during pregnancy, as it avoids expectant parents being faced 
with a prenatal diagnosis and possibly a decision on whether to 
selectively terminate an affected pregnancy as the only way of 
avoiding the birth of an affected child.
Until recently, carrier screening was generally available for 
one or a very small number of conditions within ethnic sub-
groups of the population that have a relatively high prevalence 
of those conditions. Examples include carrier screening offered 
to the Ashkenazi Jewish population for Tay–Sachs disease and 
to Mediterranean populations for beta-thalassemia (2–4). In 
more recent years, the possibility of expanded carrier screening 
has emerged. This involves simultaneously screening for carrier 
status for multiple diseases, which can be offered to all members 
of a pan-ethnic population, regardless of family history or 
ancestry (5–7). This has been made feasible through advances in 
genotyping and genetic sequencing technologies, which enable 
the concurrent evaluation of genetic mutations for large num-
bers of recessive diseases, for relatively low additional cost (5). 
Commercial companies have already developed expanded carrier 
screening tests that can screen for more than 100 recessive dis-
eases at one time and these are being offered direct-to-consumers 
at a cost (8, 9). However, only consumers who are willing and can 
afford to pay for these screening tests are able to undertake them.
For carrier screening to be truly universal, it requires a publicly 
funded approach to ensure equity of access. To warrant public 
funding, there needs to be an evidence-based assessment of the 
appropriateness of expanded carrier screening against a range of 
predetermined criteria (10). This is because, like all population-
based screening programs, carrier screening has the potential to 
result in harm as well as benefits (11). Therefore, there must be a 
rigorous assessment before implementing a publicly funded pro-
gram, to ensure that the benefits outweigh the harms. The “gold 
standard” criteria for evaluating population-based screening 
were developed for the World Health Organization over 40 years 
ago by Wilson and Jungner (12, 13). These screening pioneers 
suggested assessing evidence against 10 principles that explore 
four themes: (1) the condition being screened, (2) the test, (3) the 
treatment, and (4) the screening program.
Conclusion: A wide range of issues require careful consideration by governments 
that want to assess expanded carrier screening. Traditional criteria for government 
decision-making regarding screening programs are not a “best fit” for expanded carrier 
screening and new models of decision-making with appropriate criteria are required. 
There is a need to define what a “severe” condition is, to build evidence regarding the 
reliability and accuracy of screening tests, to consider the equitable availability and 
downstream effects on and costs of follow-up interventions for those identified as carri-
ers, and to explore the ways in which the components of a screening program would be 
impacted by unique features of expanded carrier screening.
Keywords: carrier screening, expanded carrier screening, genetic carrier screening, government, public policy
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While the Wilson and Jungner principles are the benchmark 
for government decision-making in screening, the ways in which 
they have been applied in practice vary across the globe. This is 
highlighted through a recent review of the criteria for deciding 
whether to introduce screening programs in Australia, Canada, 
Denmark, Finland, France, Germany, Italy, the Netherlands, 
New Zealand, Sweden, the UK, and the USA (14). Across these 
countries, Seedat et  al. (14) identified 46 unique criteria that 
were associated with screening in general, most of which related 
to the screening program (27) as opposed to the condition (7), 
test (6), and treatment (6). Generally, the reason for expan-
sion beyond the original Wilson and Jungner principles and 
variation in government decision-making criteria is to ensure 
processes sufficiently explore the issues most pertinent to each 
local setting (15, 16).
Despite their continued application to the assessment of 
screening programs worldwide, the Wilson and Jungner prin-
ciples do not incorporate the full range of considerations for 
expanded carrier screening. A key limitation is that the criteria 
were developed without specific examination of the unique 
benefits, risks and harms that accompany genetic screening (10). 
These unique features include that most conditions screened for 
will be rare and that a genetic test is required that in most cases 
will produce personal information for both the individual having 
the test, as well as their genetic relatives. Further, in relation to 
carrier screening, it does not screen for the presence of a condi-
tion, but rather for the presence of gene mutations that might 
cause a condition in offspring, and the “treatment” following on 
from carrier screening is thus not an intervention in line with 
the classic definition. This latter point means that, should an 
individual be identified as a carrier, there is no treatment required 
since carriers are generally not affected by the condition for which 
they are a carrier. Instead, carriers are provided with information 
that will inform their reproductive choices.
While it is recognized that the Wilson and Jungner principles 
need further consideration in the context of expanded carrier 
screening, the Netherlands is so far the only country to have devel-
oped criteria specifically for assessing genetic screening including 
carrier screening (17). For other governments looking to develop 
relevant criteria, there is a lack of clear, consistent guidance in 
the literature. At the time our workshop was held, there were two 
statements of recommendations from professional bodies in the 
USA regarding expanded carrier screening along with a report 
by the UK Human Genetics Commission, and recommendations 
have subsequently been published by the European Society of 
Human Genetics (ESHG) (1, 7, 18, 19). However, the content of 
these documents varies considerably, highlighting the current 
lack of consensus. There is literature that has identified lessons 
learned and factors for the successful implementation of existing, 
usually ethnicity-based, carrier screening programs (20–23). Yet, 
to our knowledge, there has been no systematic evaluation of the 
extent to which these factors can inform decision-making criteria 
for assessing expanded carrier screening.
Given the lack of clear, consistent policy and academic guidance 
on the relevant criteria to assess expanded carrier screening, we 
believe there is a need for more research to inform governments 
of the issues they need to consider before implementing expanded 
carrier screening. In the first instance, best practice public policy 
development suggests that there is a need to understand the val-
ues, expectations, preferences, and concerns of key stakeholders 
(10). In line with this, we held an international workshop to gain 
an understanding of which issues experts considered were the 
most salient for governments to consider. We chose to focus on 
screening in the preconception period since this is considered to 
be the best timing for carrier screening to optimize reproductive 
choice (1, 24).
Method
In June 2015, we held a satellite workshop at the ESHG Conference. 
To reach experts who might want to attend the workshop, a call 
for expressions of interest was posted on the ESHG Conference 
website. Invitations were also issued to known experts in fields 
related to expanded carrier screening, with a request to forward 
the invitation to other experts who might also be interested in 
the workshop. These communications included information on 
the objectives of the workshop. One of the objectives listed was 
“to contribute to the academic literature on expanded carrier 
screening,” which would be by publishing the outcomes of the 
workshop in a peer-reviewed journal. The intention to contribute 
to the academic literature was reiterated in material sent to those 
who expressed an interest in attending the workshop, as well as 
at the beginning of the workshop while “setting the scene” and at 
the end of the workshop in relation to “next steps.” By choosing to 
participate in the workshop, which was a public event, we assumed 
that participants were giving implied consent to the workshop 
outcomes being collated, analyzed, and published in academic 
literature. We considered this a sufficient level of consent, since 
there would be no identifying information published about the 
participants and the information obtained from the workshop 
was neither personal nor private, and could not be linked to an 
individual but rather were the outcomes of group discussions in 
a public setting.
The aim of the workshop was to identify expert opinions on the 
issues that governments should consider when deciding whether 
or not to implement preconception expanded carrier screening. 
To achieve this, the workshop was structured around two design 
features, these being information provision and small group delib-
erations. The morning session of the workshop involved a series 
of presentations from nine experts in different fields relevant to 
expanded carrier screening. These presentations were designed 
to expose workshop participants to information from outside 
their field of expertise and to a range of different perspectives on 
the key issues that government policymakers might face in rela-
tion to preconception expanded carrier screening (see Table 1). 
Providing a range of perspectives was considered important as it 
was recognized that these presentations would likely frame the 
subsequent deliberations of the small groups.
Following the presentations, participants worked in small 
groups of between six and eight people to discuss and develop 
answers to three questions, namely:
 1. What are the key factors/issues that governments need to 
consider when deciding whether or not to implement publicly 
taBLe 1 | range of perspectives covered in workshop presentations.
role Focus of presentation
Clinical 
geneticist
Justifications for offering carrier screening, criteria for assessing 
public health screening, tensions in the goals of carrier 
screening, different social and cultural contexts in which 
screening can be offered, and queries regarding the conditions 
to screen
Screening 
policymaker
Criteria that guide government decision-making for population-
based screening programs, including the Wilson and Jungner 
principles, and how these could be applied to preconception 
expanded carrier screening. Issues such as benefits and harms, 
public support, understanding the condition, testing, feasibility, 
and cost
Carrier 
screening 
program 
manager
Population and genetic conditions in Israel, national carrier 
screening programs, carrier rates in the population
Health 
economist
How health economics is used in decision-making processes, 
health technology assessment including cost–benefit analysis 
and cost-effectiveness, types of healthcare costs, and the 
kinds of health economic questions that arise in the context of 
developing screening programs
Health 
consumer 
advocate
What conditions to screen, benefits, challenges related to 
infrastructure, awareness, education, and engaging people
Ethicist Commercial offers of expanded carrier screening and the range 
of conditions tested for, criteria to determine “severe” conditions, 
reproductive decision-making, individual, and social impact
Laboratory 
scientist
Carrier screening recommendations by professional bodies, test 
characteristics such as clinical utility and validity and analytic 
validity, technology that enables expanded carrier screening, 
condition/mutation selection, pathogenic variants detected and 
variants of uncertain significance, carrier frequency, education, 
and counseling
Disability 
rights 
advocate
Disability rights objections to expanded carrier screening, 
reproductive decisions after carrier screening, eugenics, in vitro 
fertilization, discrimination, condition selection
Clinical 
geneticist
The evolution of reproductive carrier screening, counseling, and 
education in the past and for expanded carrier screening
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funded, whole-population preconception carrier screening 
programs?
 2. What are the benefits of implementing publicly funded whole-
population preconception carrier screening programs?
 3. What are the risks and challenges of implementing publicly 
funded whole-population preconception carrier screening 
programs?
The outcomes for each small group were written down by a 
scribe on feedback sheets and then orally reported back to the 
large group. The information recorded by the scribes was subse-
quently analyzed to identify common themes across all groups, 
and a summary of these findings is included in this paper.
resULts
Forty-one people attended the workshop, representing a range of 
disciplines including human genetics, clinical genetics, medical 
genetics, genetic counseling, primary care, pediatrics, laboratory 
science, bioethics, population health policy, medical sociology, 
humanities, health economics, and public health genomics. 
Participants were largely employed in academia, public health 
systems, and commercial companies. The outcomes of the small 
group discussions are presented below, gathered together in line 
with the Wilson and Jungner themes of the condition, test, treat-
ment, and screening program.
Condition
There was general agreement that only “severe” or “serious” 
conditions should be included in preconception expanded car-
rier screening. However, there was concern about the lack of a 
consensus definition of “severe” and “serious,” where the line 
between “mild” and “severe” should be and why. Some par-
ticipants suggested “severe” disorders should be defined as early 
onset conditions where the child dies in the newborn or early 
childhood periods. There was a belief that screening individuals 
in line with this definition is (1) less ethically contentious than 
screening for conditions that do not result in early mortality; 
(2) avoids perceptions of eugenics; (3) has fewer implications 
for people living with diseases; and (4) is less vulnerable to the 
disability rights critique that carrier screening removes normal 
human diversity.
The lack of a definition of severity was perceived to create 
confusion regarding which conditions should be screened and 
the potential for competition between laboratories to offer more 
and more tests. There was a belief that commercial pressures and 
technology-led development of expanded carrier screening have 
the potential to result in a “slippery slope” of offering tests just 
because they are possible. Thus, participants perceived that a 
definition of severity, which could be used to determined which 
conditions to screen, may safeguard against the inappropriate 
extension of preconception expanded carrier screening programs 
to include more and more conditions, including “mild” condi-
tions. Another question raised at the workshop was whether par-
ticipants of a preconception expanded carrier screening program 
should be able to choose which conditions to be tested for, or 
whether they could be offered a panel with no option for selecting 
specific conditions to be tested for.
test
Participants argued that there is a need for robust up-to-date 
evidence about tests used in preconception expanded carrier 
screening. Specifically, evidence is needed on the following: the 
reliability of the tests (especially the negative predictive value) 
and their appropriateness for the population; the confidence 
with which the pathogenicity of the gene mutations has been 
established; clinical and analytical validity; and residual risk and 
explanations for variants of unknown significance. It was thought 
that the tests should have clinical value/utility and public accept-
ability, and economic factors including the cost of tests need to be 
considered in deciding which conditions to test for.
treatment
There were no issues raised in relation to “the treatment” of 
participants identified as carriers. This undoubtedly relates to 
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the fact that carriers of autosomal-recessive diseases are unaf-
fected by those diseases, and as such they do not need treatment. 
Carriers of X-linked diseases may sometimes be or become 
affected, depending upon multiple factors including the pattern 
of X chromosome inactivation.
screening program
For participants, there were many uncertainties around precon-
ception expanded carrier screening and the view that offering a 
program would be “uncharted waters” in the rapidly changing, 
dynamic field of genomics. A number of issues were raised 
regarding aspects of a screening program including the purpose, 
benefits and harms, target population, program acceptability, 
components of a program, and economic evaluation.
Clarity of Purpose and Expected Benefits
Participants asserted that it would be important for governments 
to consider why preconception expanded carrier screening might 
be implemented as a publicly funded program, and what would 
be the objectives, motives, rationale, and goals of such a program. 
In their view, the purpose should be “well framed” with appropri-
ate evidence of benefits and harms and ethical principles (e.g., 
autonomy and individual rights to informed healthcare choices 
and to make decisions with as much relevant information as pos-
sible). Discussions around the purpose and possible benefits of 
preconception expanded carrier screening focused on outcomes 
that might eventuate as a result of program participation. There 
were two clear perspectives on the overarching purpose or ben-
efits, namely:
• Increased autonomy through increased reproductive choices: 
the information obtained through preconception expanded 
carrier screening leads to knowledge of carrier status and this 
increases the range of reproductive choices, to include not 
having a child with the conditions screened, or
• Reduced burden of disease: preconception expanded carrier 
screening could reduce infant mortality and morbidity. This is 
when identified carriers use the information on their carrier 
status to make reproductive choices that lead to the prevention 
or avoidance of children being born with conditions that are 
“life-threatening,” “severe,” “serious,” “nasty,” and “devastating” 
and with onset during childhood. There was the belief that this 
would result in fewer sick children being born.
There were tensions between some participants, who held dif-
fering views on whether a reduction in disease burden should be 
a primary goal or a secondary benefit of preconception expanded 
carrier screening.
Other potential benefits identified by participants included:
• Reduced family burden: the avoidance of births of affected 
children was linked to the belief that this would result in less 
distress, anxiety, strain, trauma, suffering, and long-term 
effects on families, which was then perceived to improve family 
quality of life. Participants related reduced burden of disease 
and family burden to the ethical principles of beneficence and 
prevention of harm.
• Equity of access: this refers to the notion that everyone in 
the target population should have access to all aspects of 
a screening program, including the screening test as well as 
information provided prior to screening. It was suggested that 
a government funded program for the whole population would 
mean less likelihood of a user-pays system. This would enable 
lower socioeconomic and vulnerable populations to access the 
program, thereby minimizing health disparities and inequities 
in access. However, there was some doubt expressed as to 
whether a preconception expanded carrier screening program 
would really have the capacity to deliver equitable access.
• Economic value: preconception expanded carrier screening 
could reduce healthcare expenditure through reducing mor-
bidity and the subsequent need for lifetime care of people who 
are severely affected by the conditions screened.
• Consumer desire for health information: in making infor-
mation on carrier status available for those who want it, 
preconception expanded carrier screening could be beneficial 
for those people who want as much information as possible 
related to their health.
• Increased genetics awareness among the public and health 
professionals: offering a preconception expanded carrier 
screening program to the whole population could empower 
people by increasing their knowledge about genetics (genetics 
literacy) and the fact that everybody is a carrier of something.
Potential Harms
There was a view that preconception expanded carrier screening 
may increase stigma and discrimination for those identified as 
carriers, those who opt not to undergo screening and those born 
with the conditions screened. It was also thought that people living 
with the conditions screened may be disadvantaged if a reduced 
incidence of these conditions reduces the incentives to develop 
treatments and therapies. According to participants, the rights of 
those who choose not to undergo preconception expanded car-
rier screening need to be respected. Further, participants felt that 
there would need to be adequate support for people regardless 
of the reproductive choice they make following preconception 
expanded carrier screening.
Participants argued that being identified as a carrier might 
have financial implications, for example, on insurance premiums, 
and psychological impacts, such as increased anxiety or false 
expectations or reassurance that they have been “promised” a 
healthy baby. Additionally, it was suggested that a government-
sponsored preconception expanded carrier screening program 
might foster the perception of genetic testing being “routine” 
and that screening is mandated by the government, and thus not 
voluntary. People may feel social pressure, coercion, or obligation 
to participate. It might raise questions of government-sponsored 
eugenics and “where will it end?” A challenge was seen to be pro-
viding information and counseling that is “neutral,” particularly if 
there is a “strong incentive” to increase uptake to justify providing 
the program.
Target Population
The key issues explored by participants included defining the 
target population, deciding at what age to offer screening, and 
determining whether screening would be offered to both mem-
bers of a couple at the same time or to one member of a couple 
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first and only to the other if the first one is a carrier. There was 
also a perceived need for governments to understand what would 
motivate or drive decision-making around participation in a pre-
conception expanded carrier screening program. Some attendees 
reflected that the uptake rate for the program has implications 
for cost-effectiveness, and the extent to which the program could 
result in benefits such as reduced burden of disease and increased 
reproductive choice.
Acceptability
Whether preconception expanded carrier screening was “accept-
able” was raised by a number of participants. This included 
whether the general public and target population actually want 
government funded access to preconception expanded carrier 
screening, and whether clinicians and politicians would support 
such a program.
Components of a Program
Participants thought that, if a preconception expanded carrier 
screening program was to be offered by governments, there 
should be sufficient resources to invest in an “end to end service.” 
That is, the participants thought a program is not just about the 
screening test itself. Other components of a program that partici-
pants thought important for governments to consider included:
• The provision of information and education to the public, 
target population, and health professionals. Participants rec-
ommended that, as part of a program, information should be 
provided that would make the aim(s) of the program clear and 
encapsulate the benefits, risks, harms, consequences, uncer-
tainties around genetics and preconception expanded carrier 
screening, and impact on individuals and society. Further, 
there was a view that program information should also outline 
the different conditions screened, testing procedure, interpre-
tation of results, and implications. Some workshop participants 
were concerned that the public might not have the genetic 
literacy required to understand the information provided 
including the implications of results, and therefore would 
be faced with “information burden” or making reproductive 
decisions based on information that is poorly understood by 
themselves and/or health professionals. This raised a question 
around whether preconception expanded carrier screening 
would actually result in greater autonomy for couples wishing 
to make reproductive decisions.
• Informed consent. Information provision was linked to being 
able to provide informed consent to participate in a program. 
Questions were raised around what is the best way to realize 
informed consent and whether informed consent was possible 
if multiple conditions were offered for testing in the program. 
Linked to the need for informed consent was the need to pro-
vide pretest genetic counseling. Workshop participants also 
thought that posttest genetic counseling was essential to help 
program participants understand the carrier information they 
received and make informed decisions about what to do with 
the information they received.
• Clear care pathways and support for people identified as 
carriers. This included follow-up care in terms of enabling the 
reproductive choices that carriers might want to pursue (e.g., 
access to IVF or PGD). It was proposed that consideration 
would need to be given to how the preconception expanded 
carrier screening program would connect with these other 
services and what the implications of the program would be 
for other parts of the health system. According to participants, 
a preconception expanded carrier screening program needs to 
be integrated with other programs so that there are no mixed 
messages and quality is not compromised.
• Collection of data on program participants and program 
operations. There were concerns around participant privacy 
and data ownership, protection, confidentiality, sharing, and 
access.
Questions were also raised by participants around workforce 
capacity and the impact that a program may have on healthcare 
providers, how best to start the program, and whether a pilot 
study would be appropriate.
Economic Evaluation
The resources required to establish a high-quality “end to end” 
preconception expanded carrier screening program would likely 
be significant. Participants acknowledged that healthcare systems 
are experiencing both growing demand and funding ceilings. 
Consequently they argued there is a need for governments to 
prioritize spending and consider the opportunity costs of offering 
a preconception expanded carrier screening program, as opposed 
to any other program. It was thought that the establishment of a 
preconception expanded carrier screening program should not 
take resources away from providing adequate treatment of people 
who are living with the conditions screened.
There was a perceived need for governments to consider 
sustainability, cost–benefits, and cost-effectiveness, including 
direct, indirect, and intangible costs such as anxiety and other 
psychological harms. However, in making these suggestions, 
questions arose around how to best do this and what costs and 
savings should be considered and how can these be measured. 
In particular, participants questioned the best way to consider 
savings from reduced births of affected children and reduced 
long-term support for people living with severe disabilities. 
Government inertia and the difficulty of estimating costs were 
seen as inhibitors to investment in a preconception expanded 
carrier screening program.
disCUssion
Workshop findings highlight that there is a wide range of issues 
that require careful examination by governments that are assess-
ing preconception carrier screening, to ensure that the benefits 
outweigh the harms. Overlaying feedback from the workshop 
against the original Wilson and Jungner principles demonstrates 
that these are not a “best fit” for governments to assess precon-
ception expanded carrier screening. Given that only Israel has 
implemented a national program of genetic carrier screening (25) 
and only the Netherlands has developed tailored decision-making 
criteria for genetic screening, governments across the globe have 
further work ahead of them to develop criteria that could inform 
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whether to introduce preconception expanded carrier screening. 
The workshop findings provide a starting point for governments 
to begin addressing this policy gap. Specifically, a range of issues 
have been identified in relation to the conditions to be screened, 
the tests to be used, and the components that should be incorpo-
rated into a preconception carrier screening program.
When considering “the condition,” workshop participants 
agreed that screening should only ever be offered for conditions 
that are “severe” or “serious.” This aligns with the Wilson and 
Jungner concept of an “important health problem” (12). However, 
participants recognized that there is no clear, consensus definition 
of what constitutes “severe,” with different suggestions existing in 
the literature (26, 27). Without a clear definition, it is difficult 
to determine the scope of conditions that should be considered 
for inclusion in an expanded screening program. Indeed there is 
marked disparity in the composition of currently available labo-
ratory panels of conditions for expanded carrier screening (28). 
From a program perspective, a definition is essential because the 
number and type of conditions screened has follow-on implica-
tions for how the program is implemented. Specifically, it will 
impact upon components of the program such as information 
and consent requirements, as well as counseling requirements 
and treatment or follow-up options. Further, as outlined by 
workshop participants, the definition of “severe” and thus the 
conditions screened are likely to impact upon public and clinical 
perceptions of the program. If a clear definition is not developed, 
and parameters and safeguards not set, there is the potential for 
trust in a preconception expanded carrier screening program to 
be undermined. Therefore, a body of work is needed to consider 
the definition of “severe.” The definition offered by workshop 
participants is a valid starting point: “early onset conditions 
where the child dies in the newborn or early childhood period.” 
In excluding conditions that do not result in early mortality, this 
definition was perceived to be less ethically contentious and to 
have less of an impact on disability rights.
The workshop discussions around the Wilson and Jungner 
criteria for “the test” were aligned with the literature reviewed, in 
terms of the need for the test to be accurate (see Table 2). This was 
in relation to both sensitivity (low false-positives) and specificity 
(low false-negatives) and also the ability to determine meaning-
ful residual risk for individuals who test negative. The issue of 
the cost-effectiveness of the tests was also raised by workshop 
participants, and this would likely be a key consideration for 
governments within the context of the overall cost-effectiveness 
of a program.
Workshop participants did not raise any considerations for 
government in relation to Wilson and Jungner’s theme of “the 
treatment.” This demonstrates a lack of salience of this issue for 
the participants. This could be because care and follow-up for 
carrier screening does not meet the traditional definition of treat-
ment, since such screening does not result in the identification 
of people who have conditions. When coupled with the fact that 
much of the workshop discussion focused on elements of the 
screening program, the absence of discussion on treatment could 
also reflect heightened interest in the issue of “how to screen” 
as opposed to “whether to screen.” Nonetheless, the relevance of 
the Wilson and Jungner criteria associated with “the treatment” 
may be queried in relation to preconception expanded carrier 
screening. The question then becomes whether there are more 
relevant dimensions that should replace the treatment criterion. 
For example, instead of the need for treatment being available, 
should the criterion be to recommend that “interventions are 
available”? Should the issue of interventions be framed within 
the context of the reasons for participation in preconception 
expanded carrier screening, such as “a decision should need to 
be taken by the person screened” (20) or that “screening should 
potentially influence the reproductive choices made by at-risk 
participants” (19)?
In our view, it is essential that governments consider the 
availability of interventions for preconception expanded carrier 
screening, and the downstream effects on and costs of provid-
ing such interventions. In order for a screening program to be 
effective and cost-effective, there must be an intervention that 
can lead to better health outcomes for an individual. Further, 
the intervention must be effective, available, easily accessible, 
and acceptable to individuals within the target population (44). 
Importantly, government consideration should be given to the 
fact that interventions for individuals identified as carriers are not 
currently always equitably accessible. For example, IVF and PGD 
are provided in the private sector within Australia, meaning there 
can be significant costs to individuals, which may limit access for 
citizens in lower socioeconomic groups (45, 46). This means that 
Australia, and other countries where these healthcare services 
are not equitably accessible, would need to carefully consider 
its capacity to provide the follow-up interventions required for 
a population-based approach to preconception expanded carrier 
screening. Further in relation to equity, consideration would also 
need to be given to the quality of PGD and IVF services, par-
ticularly given concerns regarding false-positive screening results 
(47, 48), and the fact that the genetics workforce is not keeping 
pace with the demand for these services (49).
As with the review by Seedat et al. (14) of population-based 
screening criteria adopted across a number of countries, the 
findings of the workshop were more likely to focus on consid-
erations relating to “the screening program” as opposed to the 
condition, test, and treatment. The issues identified in relation to 
the screening program were largely those that would be relevant 
to all screening programs, not only preconception expanded 
carrier screening. These issues included the need for a program 
that is not just about the test, but rather includes components 
such as the provision of information and education, informed 
consent processes, genetic counseling, clear care pathways, data 
collection, and economic evaluation. There is a need for further 
exploration of these issues to determine in what ways, if any, these 
program components would be impacted by the unique features 
of expanded carrier screening. For example, there was recogni-
tion by workshop participants that consent should be informed, 
but what would be the impact on the ability to obtain informed 
consent, when expanded carrier screening would test for multiple 
conditions simultaneously? How would informed consent be 
defined in this context? Related to this issue, further investigation 
should examine the impact of preconception expanded carrier 
screening on the complexity, volume, and financial implications 
of pretest and posttest counseling (28).
taBLe 2 | Coverage of issues referred to in literature.
topic 
area
issue raised by workshop participants issue not raised by workshop participants
Condition  – Should be clinically severe (1, 5, 22, 23, 29, 30)  – The impact of the condition on individuals, families, and society needs 
to be understood (22)
 – It should be an important health problem (20)
 – The nature of the condition should influence the reproductive choices 
made by at-risk participants (19)
 – Conditions should have a predictable course (23)
 – The gene mutations that cause the condition should be understood, 
should have a valid clinical association with the phenotype/severity of 
the condition, and involve highly penetrant recessive inheritance (5, 7, 
19, 29)
 – There should be a high frequency of carriers in the population (30–32)
Test  – Need to assess test performance and accuracy across all gene 
mutations assayed (5, 29, 32)
 – Sensitivity (1, 5, 23, 29, 30, 32)
 – Specificity (30, 32)
 – Ability to determine meaningful residual risk for individuals who test 
negative (7, 19, 33)
 – Cost-effective (29, 32)
 – Non-invasive (32)
 – Accessible (31)
 – Straightforward interpretation of results (23)
 – Highly scalable to avoid limits to universal uptake (5, 32)
 – Limited to gene mutations that have the highest likelihood of being/are 
clearly pathogenic (1, 7)
 – Comply with laboratory guidelines that include quality control (19)
 – Inexpensive (5, 29, 32)
Treatment  – An effective treatment or intervention should be available for those 
identified as carriers (5, 20, 23)
Screening 
program
 – A clearly defined purpose and benefits of carrier screening (1, 6, 21, 23, 
32, 34)
 – Understanding of the potential harms of carrier screening, including 
physical, psychological, psychosocial, social, and ethical, which should 
all be low compared to benefits (20, 22, 35)
 – Equity and accessibility (29, 33)
 – Defining the target population and understanding their needs (23, 29, 
36)
 – Reaching, inviting, recruiting, and informing the target population, 
and informing and educating the general public, acknowledging that 
both groups probably having low awareness or knowledge of carrier 
screening and the diseases screened for (21, 33, 37, 38)
 – Age to offer and timing of screening (i.e., individuals or couples) (1, 7, 
21)
 – Participation that is voluntary and based on informed consent (1, 7, 20)
 – Consent processes and the provision of information, education, 
counseling, and support pre-screen for all participants and post-screen 
for those with positive test results, particularly about benefits and harms 
of screening, the test process, possible outcomes, interpretations of 
results, implications, and management options (1, 7, 20, 29, 30, 33, 34, 
38–41)
 – Education of healthcare providers (1, 7, 21)
 – Resources and infrastructure, including access to follow-up services 
such as preimplantation genetic diagnosis and prenatal diagnosis (29, 
30, 36, 42)
 – Public, political, and cultural attitudes toward and acceptability of carrier 
screening (1, 7, 33, 36)
 – Economic evaluations, particularly of cost–benefit and cost-effectiveness 
(1, 7, 21, 22, 32, 34)
 – Whether the program has been offered in the research setting and/or 
pilot studies and the outcomes of these studies (22, 31, 42)
 – Accredited institutions and appropriately trained professionals (1)
 – Structure of the healthcare system (public/private) and implications for 
screening (43)
 – Monitoring, evaluation/review (21, 43, 44)
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In addition to the work that is needed by governments to 
develop robust decision-making models for assessing precon-
ception expanded carrier screening, researchers should begin to 
explore a number of issues raised by the workshop participants to 
inform and complement work in the public policy space. Within 
local contexts, “societal readiness” for preconception expanded 
carrier screening could be investigated. While several potential 
benefits of expanded carrier screening were identified at the 
workshop, a number of potential harms were also discussed, 
including concerns around discrimination, eugenics, and people 
refusing to participate in a program, which could undermine the 
cost-effectiveness of program delivery. While the UK Human 
Genetics Commission (18) concluded “there are no specific 
ethical, legal or social principles that would make preconception 
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genetic testing within the framework of a population screening 
program unacceptable” (p. 1), this needs to be explored by experts 
in other local contexts, including the contention expressed 
by workshop participants around the primary purpose of this 
screening being reproductive choice and/or reduced burden 
of disease (50). Further to this, consultation and engagement 
methodologies could be developed and implemented to assess 
stakeholder acceptability of preconception expanded carrier 
screening, including the public, target population, disease asso-
ciations, clinicians, and laboratory staff. For the target popula-
tion, this should also include investigation of likely uptake and 
postscreening decisions around reproductive choices. A recent 
study in the Netherlands has made initial contributions in the 
area of citizens/user perceptions of expanded carrier screening 
(51), while a qualitative study in Sweden has examined healthcare 
professionals’ views on preconception carrier screening (52). This 
line of work must be extended to further local contexts.
This paper has several limitations. Workshop participants were 
self-selected and may not be a representative sample of experts 
relevant to preconception expanded carrier screening. This may 
impact on the generalizability of the workshop findings. It is also 
important to note that, in relation to the literature on existing car-
rier screening programs and recommendations by professional 
bodies regarding expanded carrier screening, not all of the issues 
raised in the literature as key success factors or recommenda-
tions for implementation were addressed by the participants (see 
Table 2). During the workshop, participants were exposed to a 
range of perspectives related to preconception expanded carrier 
screening, which framed the subsequent discussions, and not 
all perspectives were covered by the workshop presentations. 
Participant exposure to other perspectives may have resulted in 
different workshop outcomes. Finally, as noted above, the work-
shop findings were reasonably high-level and did not drill down to 
deeper levels of analysis regarding the key issues. Therefore, while 
the findings provide useful guidance, a more precise exploration 
of each issue may be required to develop a comprehensive view of 
the factors governments need to consider when deciding whether 
to implement preconception expanded carrier screening.
The international workshop was an important opportunity for 
expert stakeholders in the field of preconception expanded carrier 
screening to come together to share their values, experiences and 
knowledge. The workshop outcomes identified benefits, harms, 
and other key issues that governments should consider when 
assessing whether to publicly fund preconception expanded 
carrier screening programs. This is particularly useful since most 
countries globally do not have decision-making frameworks 
related to emerging genetic screening options and are at the 
formative stage of making assessments about preconception 
expanded carrier screening.
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